Literature DB >> 16439824

Pharmacokinetics of fluoxetine in elderly men and women.

James M Ferguson1, Heather Hill.   

Abstract

Fluoxetine is widely prescribed as an antidepressant for geriatric patients. Despite a large scientific literature describing its efficacy and safety, there are few published data describing the pharmacokinetics of fluoxetine in the elderly. Given the common practice of polypharmacy in this population, additional pharmacokinetic information in elderly men and women is needed so that physicians can better assess potential drug-drug interactions. Twenty-five subjects, men and women between ages 65 and 83, received 20 mg of fluoxetine for 1 week followed by 40 mg for 5 weeks. Serum fluoxetine levels were measured during the period of drug administration and for 8 weeks after. The plasma concentration of fluoxetine and norfluoxetine in our subjects was higher than previously reported in the literature. Elderly women had a significantly higher serum level of norfluoxetine than men. The terminal half-life of norfluoxetine was longer in patients over age 75; elderly women had a significantly slower rate of norfluoxetine elimination than similarly aged men. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439824     DOI: 10.1159/000089825

Source DB:  PubMed          Journal:  Gerontology        ISSN: 0304-324X            Impact factor:   5.140


  8 in total

1.  Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation.

Authors:  Baoman Li; Shiquen Zhang; Min Li; Leif Hertz; Liang Peng
Journal:  Psychopharmacology (Berl)       Date:  2009-08-07       Impact factor: 4.530

2.  Prozac during puberty: distinctive effects on neurogenesis as a function of age and sex.

Authors:  G E Hodes; L Yang; J Van Kooy; J Santollo; T J Shors
Journal:  Neuroscience       Date:  2009-07-02       Impact factor: 3.590

3.  Sex-specific effects of chronic fluoxetine treatment on neuroplasticity and pharmacokinetics in mice.

Authors:  Georgia E Hodes; Tiffany E Hill-Smith; Raymond F Suckow; Thomas B Cooper; Irwin Lucki
Journal:  J Pharmacol Exp Ther       Date:  2009-10-14       Impact factor: 4.030

4.  Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels.

Authors:  Stuart J Warden; Sean M Hassett; Julie L Bond; Johanna Rydberg; Jamie D Grogg; Erin L Hilles; Elizabeth D Bogenschutz; Heather D Smith; Robyn K Fuchs; M Michael Bliziotes; Charles H Turner
Journal:  Bone       Date:  2010-01-06       Impact factor: 4.398

5.  Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors.

Authors:  Corine Ekhart; Florence van Hunsel; Joep Scholl; Sieta de Vries; Eugene van Puijenbroek
Journal:  Drug Saf       Date:  2018-07       Impact factor: 5.606

Review 6.  Potential Adverse Cardiovascular Effects of Treatment With Fluoxetine and Other Selective Serotonin Reuptake Inhibitors (SSRIs) in Patients With Geriatric Depression: Implications for Atherogenesis and Cerebromicrovascular Dysregulation.

Authors:  Zoltan Ungvari; Stefano Tarantini; Andriy Yabluchanskiy; Anna Csiszar
Journal:  Front Genet       Date:  2019-09-20       Impact factor: 4.599

7.  Higher dose weekly fluoxetine in hemodialysis patients: A case series report.

Authors:  Kelley M Kauffman; Jacqueline Dolata; Maria Figueroa; Douglas Gunzler; Anne Huml; Julie Pencak; Ashwini R Sehgal; Martha Sajatovic
Journal:  Int J Psychiatry Med       Date:  2020-03-26       Impact factor: 1.210

8.  Psychotropic drug-induced hyponatremia: results from a drug surveillance program-an update.

Authors:  Johanna Seifert; Martin Letmaier; Timo Greiner; Michael Schneider; Maximilian Deest; Christian K Eberlein; Stefan Bleich; Renate Grohmann; Sermin Toto
Journal:  J Neural Transm (Vienna)       Date:  2021-07-01       Impact factor: 3.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.